Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.
By H. Burstein, S. Temin, Holly Anderson, T. Buchholz, N. Davidson, K. Gelmon, S. Giordano, C. Hudis, Diana Rowden, Alexander J Solky and 3 more. Journal of Clinical Oncology, 2014
736 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/ff6846696101e003cc7ddf3e2e629fd83a5c3420
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Pulmonary and Respiratory Medicine
Citations in the corpus
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018, background): “The Panel recommended that premenopausal women who are at high risk for recurrence and have concluded 5 years of tamoxifen should extend endocrine therapy for up to 10 years (Table 4) [35].”